Calidi BiotherapeuticsCLDI -5.70%12 5-Year ROIIC % is 372.69 as of Dec. 2025. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,177 Biotechnology companies, Calidi Biotherapeutics ranks better than 92.1% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Calidi Biotherapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 372.69%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Calidi Biotherapeutics's 5-Year ROIIC % or its related term are showing as below:
CLDI's 5-Year ROIIC % is ranked better than 92.1% of 1177
companies
in the Biotechnology industry
Industry Median: -11.04
vs CLDI: 372.69
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Calidi Biotherapeutics 5-Year ROIIC % Related Terms
Calidi Biotherapeutics 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Calidi Biotherapeutics's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLDI vs DCOY, CDT, ACUT: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, Calidi Biotherapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's 5-Year ROIIC % falls into.
Calidi Biotherapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -20.19 (Dec. 2025) - -6.773 (Dec. 2020) )
/
( 4.117 (Dec. 2025) - 7.717 (Dec. 2020) )
=
-13.417
/
-3.6
=
372.69%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Calidi Biotherapeutics (CLDI) has a 5-Year ROIIC % of 372.69 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Calidi Biotherapeutics and its competitors. According to the industry distribution chart, Calidi Biotherapeutics ranks #93 out of 1177 companies in the Biotechnology industry, placing it in the top 7.9%.
Is Calidi Biotherapeutics' 5-Year ROIIC % too high?
Calidi Biotherapeutics' current 5-Year ROIIC % is 372.69. Based on the distribution chart, Calidi Biotherapeutics ranks #93 out of 1177 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' 5-Year ROIIC % compare to DCOY and CDT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #93 out of 1177 companies for 5-Year ROIIC %. This places Calidi Biotherapeutics in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current 5-Year ROIIC % is 372.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current 5-Year ROIIC % of 372.69. The current 5-Year ROIIC % is 372.69. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current 5-Year ROIIC % is 372.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score
Get the complete analysis for CLDI
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
